Freeflow Ventures
VC Fund
Pasadena, United States
Freeflow Ventures is a VC fund in Pasadena focused on Biotechnology and Medical. Freeflow is a venture firm focused on making pre-seed and seed-stage investments in new companies working to solve complex problems in human and planetary health, and which have a direct connection to the California Institute of Technology (“Caltech”) and the Jet Propulsion Laboratory (“JPL”), an operating division of Caltech, in Pasadena, CA.The GPs are David Fleck and Kevin Barrett, two longtime technology, life sciences and healthcare industry veterans who bring more than 50 combined years of technology and healthcare industry experience. Fred Wilson (Union Square Ventures), Chris Farmer (SignalFire) and Chris Douvos (Ahoy) represent the board of advisors and are also investors. To date our syndicate partners include: 8VC, Sequoia, Coatue, Catalio Capital Management, Nexus Venture Partners, OrbiMed, Embark Ventures, Dolby Family Ventures, Hillhouse Capital, Cultivation Capital, Techstars, Synovia Capital, Heritage, Wilson Hill, and Caltech.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 6%
- Fund size:
- $15M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Freeflow Ventures invests in
Stages Freeflow Ventures invests in
Countries Freeflow Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $536k–$7M
- Pre-Seed
- $1M–$3.8M
- Series A
- $3M–$52M
Investment Focus
Industry
- Biotechnology 10 (31%)
- Medical 5 (16%)
- Health Care 5 (16%)
- Life Science 5 (16%)
- Therapeutics 4 (13%)
Stage
- Seed 12 (38%)
- Series A 9 (28%)
- Pre-Seed 5 (16%)
- Series B 1 (3%)
- Funding Round 1 (3%)
Country
- United States 24 (75%)
- India 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Fleck
Founder and General Partner
|
Founder and General Partner | Total investments: 1 | Find email | |
Kevin C. Barrett
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TippingPoint Biosciences is developing therapeutics that target genome packaging states in diseases like cancer. | $4.5M / Seed / Mar 31, 2026 | ||
| Vivere develops targeted cancer therapies that activate the immune system to detect and destroy tumors using engineered bio-platforms. | $10M / Seed / Jan 13, 2026 | ||
| Sift Biosciences is a biotechnology research company that offers cancer therapies. | $3.8M / Pre-Seed / Dec 19, 2025 | ||
| Erg Bio is a biomanufacturing company enabling affordable, local production of sustainable fuels and chemicals from non-food biomass. | $6.5M / Seed / Nov 18, 2025 | ||
| The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M / Nov 10, 2025 | ||
| PINC Technologies is a Caltech spinout that creates sophisticated integrated nonlinear photonic circuits and devices. | Seed / Oct 01, 2025 | ||
| C-Quester is a carbon capture startup that offers point source emitters, primarily natural gas powerplants, the ability to absorb CO2 emissions at a 40% lower cost than existing systems. | $4.3M / Seed / Feb 25, 2025 | ||
| MIIST Therapeutics is a pulmonary drug delivery system and digital platform that enhances the science of inhaled drugs. In order to reduce the excessive quantity of death and sickness brought on by tobacco use, MIIST is actively developing technology that will be used as a smoking cessation therapy. | $7M / Seed / Feb 05, 2025 | ||
| Biomanufacturing Scale-Up Solution | $3.1M / Pre-Seed / Feb 01, 2025 | ||
| Aralez Bio uses engineered enzymes to make valuable products in a sustainable way.The company has invented a novel enzymatic method for synthesizing noncanonical amino acids (ncAAs) also called unusual or unnatural amino acids. Its proprietary approach enables over 100 ncAAs to be synthesized with perfect enantiopurity in just a single step, withwater as the only byproduct | $12M / Series A / Oct 29, 2024 | ||
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Freeflow Ventures invest in?
Freeflow Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Freeflow Ventures invest in?
Freeflow Ventures typically joins rounds of $536k–$7M at Seed, $1M–$3.8M at Pre-Seed and $3M–$52M at Series A. These are whole funding-round sizes, not Freeflow Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Freeflow Ventures took part in.
How do I contact Freeflow Ventures?
Public channels for Freeflow Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Freeflow Ventures?
The team at Freeflow Ventures includes David Fleck (Founder and General Partner) and Kevin C. Barrett (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
